Publications by authors named "Isabelle Plo"

Claim this Profile
M
MCM8- and MCM9 Deficiencies Cause Lifelong Increased Hematopoietic DNA Damage Driving p53-Dependent Myeloid Tumors.
Malik Lutzmann, Florence Bernex, Cindy da Costa de Jesus, Dana Hodroj, Caroline Marty, Isabelle Plo

Cell Rep· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Telomere occupancy by TRF2 is altered by KIT mutations and correlates with mastocytosis regression.
Julie Bruneau, Sophie Georgin-Lavialle, Sophia Ladraa, Zakia Belaid, Isabelle Plo

Blood Cancer J· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IFN-I-Mediated Transcriptional Reprogramming Drives Myeloid-skewed Hematopoiesis in Sickle Cell Anemia.
Marion Serra, Marine Aglave, Mohammad Salma, Steven Akkaya, Patricia Hermand, Isabelle Plo

Res Sq· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Type 2 calreticulin mutations activate ATF6 to promote BCL-xL-mediated survival in myeloproliferative neoplasms.
Nicole S Arellano, William L Heaton, Mirielle C Nauman, Abigail E Runnels, Jacky Gomez-Villa, Isabelle Plo

Blood· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased RhoA pathway activation downstream of αIIbβ3/SRC contributes to heterozygous Bernard Soulier syndrome.
Larissa Lordier, Christian A Di Buduo, Alexandre Kauskot, Nathalie Balayn, Cécile Lavenu-Bombled, Isabelle Plo

Haematologica· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
J
JAK2 inhibition mediates clonal selection of RAS pathway mutations in myeloproliferative neoplasms.
Nabih Maslah, Nina Kaci, Blandine Roux, Gabriela Alexe, Raphael Marie, Isabelle Plo

Nat Commun· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dissecting JAK2V617F's double life with and without MPL.
Isabelle Plo, Caroline Marty

Blood· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expanding the phenotypic and genetic landscape of congenital neutropenia through whole-exome and genome sequencing.
Séverine Marti, Philippe Pellet, Blandine Beaupain, Léa Durix, Julien Buratti, Isabelle Plo

Hemasphere· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of Hepatic-like EPO as a Cause of Polycythemia.
Laurent Martin, Darko Maric, Salam Idriss, Marine Delamare, Amandine Le Roy, Isabelle Plo

N Engl J Med· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New approaches to standard of care in early-phase myeloproliferative neoplasms: can interferon-α alter the natural history of the disease?
Florence Pasquier, Jean Pegliasco, Jean-Edouard Martin, Severine Marti, Isabelle Plo

Haematologica· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Monocytes generated by interleukin-6-treated human hematopoietic stem and progenitor cells secrete calprotectin that inhibits erythropoiesis.
Valentine Marchand, Lucie Laplane, Louis Valensi, Isabelle Plo, Marine Aglave

iScience· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective targeting of mutated calreticulin by the monoclonal antibody INCA033989 inhibits oncogenic function of MPN.
Edimara S Reis, Rebecca Buonpane, Hamza Celik, Caroline Marty, Angela Lei, Isabelle Plo

Blood· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impaired fibrinolysis in JAK2V617F-related myeloproliferative neoplasms.
Marie-Charlotte Bourrienne, Stéphane Loyau, Dorothée Faille, Juliette Gay, Séléna Akhenak, Isabelle Plo

J Thromb Haemost· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of MPL K39N and R102P heterozygous germline mutations lead to hereditary thrombocytosis.
Emeline Voirin, Anne Bouvier, Isabelle Plo, Léa Durix, Annaëlle Beucher

Am J Hematol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exacerbation of thromboinflammation by JAK2V617F mutation worsens the prognosis of cerebral venous sinus thrombosis.
Marie-Charlotte Bourrienne, Véronique Le Cam Duchez, Dorothée Faille, Carine Farkh, Mialitiana Solo Nomenjanahary, Isabelle Plo

Blood Adv· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mathematical modelling, selection and hierarchical inference to determine the minimal dose in IFNα therapy against myeloproliferative neoplasms.
Gurvan Hermange, William Vainchenker, Isabelle Plo, Paul-Henry Cournède

Math Med Biol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deregulation of the p19/CDK4/CDK6 axis in Jak2 megakaryocytes accelerates the development of myelofibrosis.
Hélène Duparc, Delphine Muller, Laure Gilles, Agathe L Chédeville, Mira El Khoury, Isabelle Plo

Leukemia· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Natural history of myeloproliferative neoplasms by a phylogenetic tree-based approach].
Jackson Josil, Eva Thuillier, Laetitia Chambrun, Isabelle Plo

Med Sci (Paris)· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The double-edged sword of adenosine.
Isabelle Plo, Iléana Antony-Debré

Haematologica· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing IFN Alpha Therapy against Myeloproliferative Neoplasms.
Gurvan Hermange, Paul-Henry Cournède, Isabelle Plo

J Pharmacol Exp Ther· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution.
Alba Rodriguez-Meira, Ruggiero Norfo, Sean Wen, Agathe L Chédeville, Haseeb Rahman, Isabelle Plo

Nat Genet· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recent advances in therapies for primary myelofibrosis.
William Vainchenker, Nasrine Yahmi, Violaine Havelange, Caroline Marty, Isabelle Plo

Fac Rev· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
When monoclonal gammopathy-associated chronic neutrophilic leukemia is a reactive process distinct from a clonal myeloproliferative neoplasm: Lessons from mistakes.
Christophe Willekens, Claude Chahine, Matteo Dragani, Sabine Khalife-Hachem, Camille Bigenwald, Isabelle Plo

EJHaem· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting PP2A-dependent autophagy enhances sensitivity to ruxolitinib in JAK2 myeloproliferative neoplasms.
Charly Courdy, Loïc Platteeuw, Charlotte Ducau, Isabelle De Araujo, Emeline Boet, Isabelle Plo

Blood Cancer J· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SRSF2-P95H decreases JAK/STAT signaling in hematopoietic cells and delays myelofibrosis development in mice.
Christophe Willekens, Lucie Laplane, Tracy Dagher, Camelia Benlabiod, Nicolas Papadopoulos, Isabelle Plo

Leukemia· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis